Record overview
Status and phase
Status: TERMINATED
Phase: PHASE2
Sponsor: Providence Health & Services
Condition: Refractory Cutaneous Melanoma
NCT05200143
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Registry Stop Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
Withdrawn support from BMS.